Description

McMMAF is a protective group (maleimidocaproyl)-conjugated MMAF, which is a potent tubulin polymerization inhibitor. McMMAF can be used as a agent-linker for antibody-drug conjugates (ADC). McMMAF is uncleavable, and must be internalized and degraded within a cell, releasing cysteine-McMMAF as the active agent[1][2].–20°C (Powder, stored under nitrogen)-Applications-Cancer-programmed cell death-Formula-C49H76N6O11-Citation–References-[1]Polson AG, et al. Antibody-drug conjugates for the treatment of non-Hodgkin’s lymphoma: target and linker-drug selection. Cancer Res. 2009 Mar 15;69(6):2358-2364.|[2]Jianmin Fang, et al. Anti-her2 antibody and conjugate thereof. US 20160304621 A1.-CASNumber-863971-19-1-MolecularWeight-925.16-Compound Purity-99.96-SMILES-O=C([C@H](C)[C@H]([C@]1([H])CCCN1C(C[C@@H](OC)[C@@]([H])(N(C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C(CCCCCN2C(C=CC2=O)=O)=O)=O)=O)C)[C@@H](C)CC)=O)OC)N[C@H](C(O)=O)CC3=CC=CC=C3-Research_Area-Cancer-Solubility-DMSO : ≥ 100 mg/mL-Target-Drug-Linker Conjugates for ADC-Isoform-Auristatin-Pathway-Antibody-drug Conjugate/ADC Related-MCE Product type-ADC Related